CD40 Agonist - Pipeline Insight, 2018

"CD40 Agonist- Pipeline Insight, 2018" report by DelveInsight outlays comprehensive Insight of present scenario and growth prospects across CD40 Agonist. A detailed picture of the pipeline landscape is provided with summation of data from multiple sources with complete analysis by development stage, mechanism of action, route of administration and molecule type. This report provides detailed analysis of 10+ products along with 10+ companies involved.
Products covered by Phase
• Phase II and Phase I
• Pre-clinical
• Inactive (Dormant and Discontinued)
Overview of pipeline development activities for CD40 Agonist
Pipeline analysis of therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and pre-clinical results, designations, collaborations & licensing deals, grants, technology and patent details.
Therapeutic segmentation of products for CD40 Agonist
The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this mechanism.
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
Scope of the report
• Provides an overview of therapeutic pipeline activity for CD40 Agonist across the complete product development cycle including all clinical and non-clinical stages
• It comprises of detailed profiles of CD40 Agonist therapeutic products with key coverage of developmental activities including licensing & collaboration deals, patents issued, designations, technologies and chemical information
• Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
• Coverage of dormant and discontinued pipeline projects across CD40 Agonist

Reasons to Buy
• Establish a comprehensive understanding of the current pipeline scenario across CD40 Agonist to formulate effective R&D strategies
• Assess challenges and opportunities that influence CD40 Agonist R&D
• Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Identify the relationship between the products and use it for target finding, drug repurposing, and precision medicine
• Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for CD40 Agonist to enhance and expand business potential and scope
• Our extensive domain knowledge on therapy areas support the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs
CD40 Protein
Structure and Expression
Mechanism of Action
Role in Cancer
CD40 Pathway as Therapeutic Target
Pipeline Therapeutics (Active Products)
Comparative Analysis
Mid-Stage Products (Phase II)
Comparative Analysis
APX005M: Apexigen
Product Description
Research and Development
Product Development Activity
(The list continues)
Early Stage Products (Phase I)
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Dormant and Discontinued Products
Comparative Analysis

List of Figures, Tables and Charts Available in CD40 Agonist - Pipeline Insight, 2018

Table 1: Total Products for CD40 agonist
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-Clinical Stage Products
Table 5: Assessment by Route of Administration for CD40 agonist
Table 6: Assessment by Stage and Route of Administration
Table 7: Assessment by Molecule Type
Table 8: Assessment by Stage and Molecule Type
Table 9: Dormant and Discontinued Products

Figure 1: Functional Consequences Of CD40 Signaling
Figure 2: TRAF And Jak3 Dependent CD40 Signalling Pathway
Figure 3: Role Of CD40 In Immune Response Against Cancer
Figure 4: Total Products for CD40 agonist
Figure 5: Mid Stage Products (Phase II)
Figure 6: Early Stage Products (Phase I)
Figure 7: Pre-Clinical Stage Products
Figure 8: Product Type
Figure 9: Assessment by Route of Administration
Figure 10: Assessment by Stage and Route of Administration
Figure 11: Assessment by Molecule Type
Figure 12: Assessment by Stage and Molecule Type
Figure 13: Dormant and Discontinued Products

Keyplayers in CD40 Agonist - Pipeline Insight, 2018

Cellular Biomedicine Group
Janssen Biotech
Seattle Genetics
Celldex Therapeutics
University of Southampton
Seattle Genetics